Samrat Pharmachem Reports Declining Profitability Metrics in March 2025 Results

Samrat Pharmachem has recently reported its financial results for the quarter ending March 2025, revealing notable shifts in its performance metrics. The company's score has undergone an adjustment, reflecting a change from 18 to -5 over the past three months.
The financial data indicates challenges for Samrat Pharmachem, particularly in its profitability metrics. The Profit Before Tax less Other Income (PBT) for the quarter stands at Rs -0.25 crore, marking a significant decline compared to the average PBT of Rs 2.57 crore from the previous four quarters. Similarly, the Profit After Tax (PAT) has also shown a downward trend, recorded at Rs -0.40 crore, which is substantially lower than the average PAT of Rs 2.23 crore in the prior quarters.

Additionally, the Operating Profit (PBDIT) has reached its lowest point in the last five quarters at Rs 0.12 crore, indicating a negative trend in operational efficiency. The Operating Profit Margin has also decreased to 0.17%, further highlighting the company's struggles in maintaining profitability. The Earnings per Share (EPS) has fallen to Rs -1.29, reflecting a decline in shareholder earnings.

Overall, these financial results suggest a challenging environment for Samrat Pharmachem, prompting a revision in its evaluation.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.